

From: Alicea, Candido  
Sent: Sunday, March 24, 2019 4:28 PM  
To: 'joan.robertson@grifols.com'  
Subject: Information Request #23: BLA 125683/0, Grifols Therapeutics LLC Immune Globulin Subcutaneous (Human), 20%

Our Reference: BLA 125683/0

Dear Ms. Robertson:

We are reviewing your July 9, 2018, original biologics license application for Immune Globulin Subcutaneous (Human), 20%. We are requesting that you make the following amendment:

1. Please clarify for the Polio Potency specification whether the (b) (4) CBER Reference refers to product that has been (b) (4), and also please update the Polio Potency lot release wording accordingly.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please provide your response by COB April 1, 2019 and submit your response to this information request as an amendment to your BLA referencing the date of this request.

If you have any questions, please contact me at (240) 402-8310.

Regards,  
Candido

Cándido Alicea Ph.D.  
CDR, USPHS  
Regulatory Project Manager  
Center for Biologics Evaluation and Research  
Office of Tissues and Advanced Therapies  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8310  
Fax: 301-595-1303  
candido.alicea@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."